- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 | 1 | RTTNews | ||
| 08.04. | Nuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines | 70 | GlobeNewswire (Europe) | Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant... ► Artikel lesen | |
| 19.03. | Nuvectis Pharma CEO acquires $51k in company stock | 1 | Investing.com | ||
| 19.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting | 1 | GlobeNewswire (USA) | ||
| 15.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma to Present at the 36th Annual Roth Conference | 1 | GlobeNewswire (USA) | ||
| 14.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer | 80 | GlobeNewswire (Europe) | 33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious... ► Artikel lesen | |
| 05.03. | Nuvectis Pharma, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 05.03. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights | 64 | GlobeNewswire (Europe) | NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800... ► Artikel lesen | |
| 09.02. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences | - | GlobeNewswire (USA) | ||
| 08.11.23 | Nuvectis Pharma Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
| 08.11.23 | Nuvectis Pharma GAAP EPS of -$0.37 | 1 | Seeking Alpha | ||
| 08.11.23 | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.11.23 | Recap: Nuvectis Pharma Q3 Earnings | 1 | Benzinga.com | ||
| 08.11.23 | Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights | 188 | GlobeNewswire (Europe) | Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid TumorsNXP800... ► Artikel lesen | |
| 08.11.23 | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08.23 | Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights | 264 | GlobeNewswire (Europe) | The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoingNXP900 IND cleared by the US FDA, start of Phase 1a study expected in Q3 2023 FORT... ► Artikel lesen | |
| 10.05.23 | Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights | 274 | GlobeNewswire (Europe) | Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,535 | -5,25 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,824 | -4,19 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,990 | 0,00 % | Ginkgo Bioworks surges as much as 31%, though pares gains | ||
| BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +1,98 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,630 | +0,30 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,848 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,830 | +0,46 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,740 | +0,07 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,370 | +1,70 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,260 | +1,62 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,600 | +2,99 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,850 | 0,00 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,750 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen NUVECTIS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,380 Euro und damit -1,85 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
